Quince may end Phase 3 NEAT enrollment early in June 2025 to align cash runway with topline results in early 2026

Quince Therapeutics, Inc.

63 participants enrolled to date (56 in primary analysis population ages 6–9); original target was 86.
Early enrollment conclusion by end of June would provide ~80% power for primary endpoint.
Cash and investments $31.6M; net loss Q1 2025 of $15.0M ($0.34 per share).
Topline results expected early 2026; NDA/MAA submissions planned H2 2026 if positive.
All 19 study sites activated; slower enrollment cited due to challenging academic site environment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.